Forte Biosciences Reports Increased Net Loss, Secures Funding, and Advances Clinical Pipeline
FBRX has more than doubled off its 52-week low of $4.9.
Summary
Forte Biosciences reported a net loss of $69.4 million for 2025 but highlighted successful capital raises, positive clinical data for its lead candidate FB102 in celiac disease, and an extended cash runway of at least 12 months.
Key Events · Earnings and Guidance · FBRX
-
Increased Net Loss for 2025
The company reported a net loss of $69.4 million for the year ended December 31, 2025, a significant increase from $35.5 million in 2024, primarily due to increased research and development expenses.
-
Extended Cash Runway
As of December 31, 2025, Forte Biosciences had $77.0 million in cash and cash equivalents, which management believes will be sufficient to fund operations for at least 12 months from the filing date.
-
Clinical Pipeline Advancement
Positive Phase 1b data for FB102 in celiac disease was announced in June 2025, leading to the initiation of a Phase 2 study in July 2025, with FDA IND approval for a US arm in November 2025. Phase 1b trials for non-segmental vitiligo and alopecia areata are also underway with topline data expected in 2026.
-
Successful Capital Raises
The company completed a public offering in June 2025, raising $75.0 million, and a private placement in November 2024, raising $53.0 million, significantly bolstering its financial resources.
Analysis · FBRX · Life Sciences
This annual report provides a comprehensive update on Forte Biosciences' financial health and clinical development. While the company reported a significant increase in net loss for 2025, it successfully executed substantial capital raises in 2024 and 2025, extending its cash runway to at least 12 months. Positive Phase 1b clinical data for its lead candidate, FB102, in celiac disease, and subsequent progression to Phase 2, along with FDA IND approval, are critical advancements for a clinical-stage biopharmaceutical company. The legal recovery further bolsters its financial position. Investors should monitor the progress of ongoing clinical trials and future financing needs.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FBRX was trading at $26.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $324.4M. The 52-week trading range was $4.90 to $35.62. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.